Announced Mon, 20 Jul · 09:00 IST

Beta Drugs Q1FY27 results: revenue up 25%, PAT jumps 41%

Revenue Growth 20pctPat Growth 25pctEbitda Margin ExpansionResults View source PDF

BETA · price

Loading chart…

▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.

Price reaction · full curve 14 horizons · vs prior close

+11.0%1-day move

₹2233.00

prior close

₹2299.00

base price

After-mkt

timing

5m10m15m30m1D2D3D4D5D7D15D1M2M3M

+2.6+2.3+2.6+8.4+11.0+4.8+2.2+4.6-0.2—————

Up moveDown movePending

AI summary

Beta Drugs posted Q1FY27 consolidated revenue of Rs 127.13 crores, up about 25% YoY. Net profit rose nearly 41% to Rs 16.5 crores with margin at 13.1%. EBITDA excluding other income grew 38.9% to Rs 27.37 crores with margins at 21.8%. Branded oncology grew 47%, CMO 41% and Nivian 45% YoY. Exports stood at Rs 17.2 crores. Gross margins expanded to 56.6% from 50.4% on better sales mix. Finance costs fell after CCD conversion. Auditor issued a clean limited review. Company guides 20-25% FY27 growth.

Likely market impact

Strong broad-based growth with margin expansion and clean audit. Positive FY27 guidance of 20-25% growth supports the stock story.